BRAF and non-small cell lung carcinoma: Therefore, this study retrospectively analyzed the demographics and molecular characteristics between primary and acquired BRAF-mutated patients, as well as the triple-treatment regimen efficacy in these groups, and provided a new option for the treatment of primary and acquired BRAF-mutated NSCLC patients.